In the latest quarter, 5 analysts provided ratings for Quest Diagnostics ( DGX ) , showcasing a mix of bullish and bearish perspectives.

The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.

Analysts have recently evaluated Quest Diagnostics ( DGX ) and provided 12-month price targets. The average target is $163.2, accompanied by a high estimate of $182.00 and a low estimate of $150.00. This current average has increased by 8.08% from the previous average price target of $151.00.

Diving into Analyst Ratings: An In-Depth Exploration

The analysis of recent analyst actions sheds light on the perception of Quest Diagnostics ( DGX ) by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Quest Diagnostics ( DGX ). This insight gives a snapshot of analysts' perspectives on the current state of the company.

Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Quest Diagnostics ( DGX ) compared to the broader market.

Price Targets: Gaining insights, analysts provide estimates for the future value of Quest Diagnostics's ( DGX ) stock. This comparison reveals trends in analysts' expectations over time.

For valuable insights into Quest Diagnostics's ( DGX ) market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.

Stay up to date on Quest Diagnostics ( DGX ) analyst ratings.

About Quest Diagnostics

Quest Diagnostics ( DGX ) is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.

Quest Diagnostics: Financial Performance Dissected

Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.

Positive Revenue Trend: Examining Quest Diagnostics's ( DGX ) financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 2.52% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.

Net Margin: Quest Diagnostics's ( DGX ) net margin is impressive, surpassing industry averages. With a net margin of 9.51%, the company demonstrates strong profitability and effective cost management.

Return on Equity (ROE): Quest Diagnostics's ( DGX ) financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 3.49%, the company showcases efficient use of equity capital and strong financial health.

Return on Assets (ROA): Quest Diagnostics's ( DGX ) ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.64% ROA, the company effectively utilizes its assets for optimal returns.

Debt Management: Quest Diagnostics's ( DGX ) debt-to-equity ratio is below the industry average. With a ratio of 0.77, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.

What Are Analyst Ratings?

Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.

Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.